Blood Acceptance Rate

Blood's 19.4 impact factor puts it alongside Nature Immunology and Immunity in citation metrics. But its acceptance rate (~15-20%) is notably higher than those journals (~8-10%). The reason: Blood publishes in a single specialty (hematology) with enormous breadth within that specialty.

The journal accepts:

• Basic hematology (stem cells, coagulation, hemoglobin biology)
• Clinical hematology (treatment outcomes, clinical trials)
• Translational hematology (bench-to-bedside in blood diseases)
• Blood banking and transfusion medicine
• Immunohematology

This breadth means more paper types find a home. A clinical trial in lymphoma, a basic study on platelet signaling, and a transfusion safety paper can all be published in the same issue. That diversifies the submission pool and raises the acceptance rate relative to narrower journals.

Blood's desk rejection rate (~40-50%) is lower than Nature or Cell (~70-80%). The editors are less concerned with "is this exciting enough?" and more concerned with "is this real hematology with adequate rigor?"

Common desk rejection reasons:

• The paper is tangentially related to blood but isn't really hematology (oncology papers about solid tumors, immunology papers without a blood connection)
• The methodology has obvious flaws that won't survive review
• The clinical study is too small or the endpoints are too weak for the claim
• The paper duplicates recently published findings without adding a new dimension

Blood reviewers are practicing hematologists and hematology researchers. They know the field deeply. Papers get rejected after review when:

• The hematology community already knows this (incremental finding)
• The model system doesn't translate well to human blood disease
• The clinical data has selection bias or endpoint problems that weren't apparent at triage
• The paper is technically correct but doesn't advance the field

Submit if:

• the finding advances hematology in a way the community will build on
• the paper is clearly hematology (blood cells, blood diseases, transfusion, coagulation)
• the methodology is rigorous enough for specialty-level scrutiny
• the clinical or translational relevance is clear for a hematology audience

Think twice if:

• the hematology connection is secondary (the paper is really oncology, immunology, or biochemistry)
• Blood Advances would be a faster path to the same audience
• JCO or Leukemia is a more natural fit for the specific topic
• the finding is incremental for the hematology community

A Blood submission readiness check can help assess whether the hematology framing and evidence strength meet Blood's editorial expectations.

In our pre-submission review work evaluating manuscripts targeting Blood, three patterns generate the most consistent desk rejections. Each reflects the journal's scope: hematology-first science with rigor appropriate for specialty scrutiny by practicing hematologists.

Tangential hematology connection in a paper that belongs in a different specialty. The Blood author instructions describe the journal as covering "all aspects of hematology," with an emphasis on papers where blood biology, blood diseases, or blood-based therapies are the central focus. The failure pattern is a paper from oncology, immunology, or biochemistry where hematology is invoked as a context but is not the driving discipline. A paper on solid tumor immunotherapy that includes a blood cell subset analysis in one figure, an autoimmune disease study where a blood biomarker is the secondary endpoint, or a protein biochemistry paper where the protein happens to be expressed in platelets does not constitute a hematology paper in Blood's editorial sense. The editors look for papers where the finding matters primarily to hematologists: people who study or treat diseases of the blood, bone marrow, and lymphoid system. Papers where the blood connection is secondary are desk-rejected and returned with a recommendation to target the journal most appropriate for the primary discipline.

Clinical study with insufficient sample size or weak endpoint for the claim. Blood publishes clinical research in hematology including treatment outcomes, clinical trial results, and real-world evidence studies. The failure pattern is a retrospective study or small prospective cohort claiming a clinical conclusion that the data do not support at adequate statistical power. A single-center retrospective study of 45 patients claiming that a novel treatment combination improves response rates compared to standard therapy, a case series of 12 patients with a rare hematologic diagnosis claiming a survival benefit, or a biomarker study without an independent validation cohort claiming clinical utility all face rejection based on insufficient evidence for the claim. Blood reviewers and editors are clinical hematologists who recognize when the sample size, follow-up duration, or endpoint selection cannot support the conclusion being drawn.

Mechanistic finding in a mouse or cell line model that does not connect to human hematology. Blood publishes basic and translational research with the expectation that results have relevance to human blood biology or disease. The failure pattern is a mechanistic study in a xenograft model, a mouse knockout, or a cell line where the connection to human hematology is asserted but not demonstrated. A study showing that deletion of gene X in murine HSCs affects engraftment, without any human HSC or patient-derived data supporting the finding, faces reviewer questions about whether the mechanism is conserved in human hematopoiesis. A drug sensitivity result in a leukemia cell line that is not validated in primary patient samples or a PDX model will receive requests for human data that may require months of additional work. The translational bar at Blood is that the basic finding should connect to a human disease context either through direct patient-derived data or through a strong mechanistic argument grounded in established human biology. A Blood submission readiness check can assess whether the translational framing and evidence package meet Blood's standard before submission.

The acceptance rate for Blood does not distinguish between desk rejections and post-review rejections. A paper desk-rejected in 2 weeks and a paper rejected after 4 months of review both count the same. The rate also does not reveal how acceptance varies by article type, geographic origin, or research area within the journal's scope.

Acceptance rates cannot predict your individual odds. A strong paper with clear scope fit, complete data, and solid methodology has substantially better odds than the headline number suggests. A weak paper with methodology gaps will be rejected regardless of the journal's overall rate.

A Blood submission readiness check identifies the specific framing and scope issues that trigger desk rejection before you submit.